Transfusion and Apheresis Science
Volume 35, Issue 1 , Pages 83-90 , August 2006

Update on pathogen reduction technology for therapeutic plasma: An overview

  • B.G. Solheim

      Affiliations

    • Institute of Immunology, Rikshospitalet-Radiumhospitalet Medical Centre, University Hospital, University of Oslo, Oslo, Norway
    • Corresponding Author InformationCorresponding author. Fax: +47 2307 3510.
    • ,
  • J. Seghatchian

      Affiliations

    • Blood Component Technology and Haemostasis/Thrombosis Consultancy, 50 Primrose Hill Road, London NW3 3AA, United Kingdom

Received 6 January 2006 ,Accepted 22 February 2006.

References 

  1. Seghatchian J. What is happening? Are the current acceptance criteria for therapeutic plasma adequate?. Transfus Apheresis Sci. 2004;31:67–79
  2. Spahn DR. Strategies for transfusion therapy. Best Pract Res Clin Anaestethesiol. 2004;18:661–673
  3. A report by the American Society of anesthesiologists task force on blood component therapy. Practice guidelines for blood component therapy. Anesthesiology. 1996;84:732–747
  4. Stainsby D, Cohen H, Jones H, Todd A, Knowles S, Taylor C, et al. Serious hazards of transfusion. Summary of annual report 2001–2002. Available from http//www.shot-uk.org.
  5. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol. 2004;11:346–350
  6. Seghatchian J, Krailadsiri P. The quality of methylene blue light treated FFP and cryopoprecipitate. Transfus Apheresis Sci. 2001;25:227–231
  7. Mohr H, Lambrecht B, Seltz A. Photodynamic virus inactivation of blood components. Immunol Invest. 1995;24:73–85
  8. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion. 2003;43:1322–1329
  9. Wieding JU, Rathgeber J, Zenker D. Prospektive, randomized and controlled study on solvent/detergent versus methylene blue/light virus inactivated plasma. Transfusion. 1999;39(Suppl.):23S
  10. Crettaz D, Sensebe L, Vu DH, Schneider P, Depasse F, Bienvenut WV, et al. Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics. 2004;4:881–891
  11. Depasse F, Sensebe L, Seghatchian J, Andreu G, Samama M-M. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerization indices. Transfus Apheresis Sci. 2005;33:63–69
  12. Atance R, Pereira A, Ramirez B. Transfusion methylene blue photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548–1552
  13. Alvarez-Larran A, Del Rio J, Ramirez C, Albo C, Pena F, Campos A, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as a replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang. 2004;86:246–251
  14. Lin L, Cook DN, Wiesebahn GP, Alfonso R, Behrman B, Cimino GD, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–435
  15. Corash L. Virus “safe” products/pathogen reduction. In:  Hillyer CD,  Silberstein LE,  Ness PM,  Anderson KC editor. Blood banking and transfusion medicine. Philadelphia: Churchill Livingstone; 2003;p. 241–251
  16. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, et al. Fresh frozen plasma prepared with amotosalem HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation deficiencies. Transfusion. 2005;45:1362–1372
  17. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT blood system. Vox Sang. 2003;85:171–182
  18. Kumar V, Lockerbie O, Kell SD, et al. Riboflavin and UV light based pathogen reduction: extend and consequence of DNA damage at molecular level. Photochem Photobiol. 2004;75:561–564
  19. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent treatment of human plasma: a virus inactivated substitute for fresh frozen plasma. Blood. 1992;79:826–831
  20. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions base don modell virus data. Transfusion. 2003;43:1023–1028
  21. Roberts P. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals. 2000;28:29–32
  22. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion. 2000;40:84–90
  23. Solheim BG, Hellstern P. Composition, efficacy, and safety of S/D-treated plasma. Transfusion. 2003;43:1176–1178
  24. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med, in press.
  25. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thrombosis Res. 2002;107:S3–S8
  26. Horowitz MS, Pehta JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang. 1998;74(Suppl. 1):231–235
  27. Williamson IM, Llewelyn CA, Fischer NC, Allain JP, Bellany MC, Bablin TP, et al. A randomized trial of solvent/detergent-treated and standard fresh frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227–1234
  28. Beck KH, Mortelmans Y, Kretschmer V, Höltermann W, Lukasewitz P. Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusther Transfus Med. 2000;27:144–148
  29. Lerner RG, Nelson J, Scorcia E, Grima K, Kancherla RR, Zarou-Naimo CM, et al. Evaluation of solvent/detergent-treated plasma in patients with prolonged prothrombin time. Vox Sang. 2000;79:161–167
  30. Fontana S, Kremer-Hovinga JA, Studt JD, Alberio L, Lammle B, Taleghani BM. Plasma therapy in thrombotic thrombopenic pupura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol. 2004;41:48–59
  31. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombopenic purpura. Br J Haematol. 2003;121:778–785
  32. Rock G, Clark B, Stutton D Members of the CAG and CAAN. The Canadian apheresis registry. Transfus Apheresis Sci. 2003;29:167–177
  33. de Jonge J, Groenland THN, Metselaar HJ, Ijzermans JNM, van Vliet HHDM, Visser L, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®). Anesth Analg. 2002;94:1127–1131
  34. Matsuda M, Wakabayashi K, Aoki N, Morioka Y. Alpha 2-plasmin inhibitor is among acute phase reactants. Thromb Res Suppl. 1980;17:527–532
  35. Solheim BG, Bergan A, Brosstad F, Innes R, Svennevig JL. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®/Octaplas®). Anesth Analg. 2003;1230–1231
  36. Solheim BG. Plasma induced TRALI is avoided with solvent/detergent-treated plasma. Transfus Alternat Transfus Med. 2005;7(Suppl):57
  37. Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang. 2005;89:1–10
  38. Tollofsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intens Care Med. 2003;29:1736–1743
  39. Solheim BG, Granov DA, Juralev VA, Krawczyk M, Kubishkin VA, Patutko UI, et al. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang. 2005;89:19–26
  40. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion. 1999;39:479–487
  41. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent–detergent-treated plasma. JAMA. 1999;282:329
  42. Riedler GF, Haycox AR, Duggan AK, Dankin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang. 2003;85:88–95

PII: S1473-0502(06)00092-9

doi: 10.1016/j.transci.2006.02.004

Transfusion and Apheresis Science
Volume 35, Issue 1 , Pages 83-90 , August 2006

Article Tools